BioCryst製藥 BCRX 深 滬
已收盤 05-08 16:00:00 美东时间
8.62
-0.280
-3.15%
華盛通- 最 高8.99
- 今 開8.96
- 成交量 616.45万股
- 最 低 8.555
- 昨 收 8.90
- 總市值 21.90亿
- 52周最高 11.31
- 市盈率 靜 7.14
- 換手率 2.43%
- 52周最低 6.00
- 委 比 32.20%
- 總股本 2.54亿
- 歷史最高 19.99
- 量 比 1.28
- 振 幅 4.89%
- 歷史最低 1.08
- 每 手 1
- 風險率 1.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
财报速睇 | BioCryst制药 2026财年Q1营收1.56亿美元，同比增长7.5%；归母净利润亏损7.22亿美元，由盈转亏
华盛资讯5月7日讯，BioCryst制药公布2026财年Q1业绩，公司Q1营收1.56亿美元，同比增长7.5%，归母净利润亏损7.22亿美元，由盈转亏。
05-07 10:47
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Needham Maintains Buy on BioCryst Pharma, Lowers Price Target to $16
Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the price target from $18 to $16.
05-07 02:19
Full Transcript: BioCryst Pharma Q1 2026 Earnings Call
BioCryst Pharma (NASDAQ:BCRX) released first-quarter financial results and host...
05-06 21:28
财报速睇 | BioCryst制药 2026财年Q1营收1.56亿美元，同比增长7.5%；归母净利润亏损7.22亿美元，由盈转亏
华盛资讯5月6日讯，BioCryst制药公布2026财年Q1业绩，公司Q1营收1.56亿美元，同比增长7.5%，归母净利润亏损7.22亿美元，由盈转亏。
05-06 19:36
BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $650.217M Est
BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to $635.000 million-$660.000 million vs $650.217 million estimate.
05-06 19:15
BioCryst Pharma Q1 Adj. EPS $0.14 Beats $0.05 Estimate, Sales $156.413M Beat $151.123M Estimate
BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.05 by 180 percent. The company reported quarterly sales of $156.413 million which beat the
05-06 19:15
BioCryst And Neopharmed Gentili Expand Partnership With European Navenibart HAE License Delivering $70M Upfront And 18-30% Tiered Royalties
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —— BioCryst to receive $70M upfront, up to $275M in future regulatory and sales
05-04 19:10
